LICENSE AGREEMENT IN LUNG CANCER AND TRADING UPDATE

6th January 2009

Proteome Sciences plc has entered into a non-exclusive license agreement with Oncimmune Limited in lung cancer for the use of its Annexin 1 and Annexin 2 autoantibody patents for the fields of diagnosis and for monitoring treatment. It is anticipated that a panel test will be launched in the first half of 2009.

Terms of the license agreement were not disclosed but Proteome Sciences will receive royalties from product sales.

Following the successful launch of TMT® reagents by Thermo Fisher earlier this year, feedback continues to be strongly favourable and the visibility of isobaric mass tagging will become increasingly apparent in revenues.

Proteome Sciences is pleased to announce that it has successfully increased the plexing rates for its TMT® tags, and that 12 and 18-plex TMT® will be available in 2009.

Proteome Sciences continues to make strong progress in other disease applications and is in advanced negotiations to out-license further candidates in its biomarker portfolio in both stroke and Alzheimer's disease and also from ProteoSHOP® services activities. Whilst these are expected to be reflected in revenue, the Board has thought it prudent to agree in principle to increase the loan facility available from the CEO, should it be required.

2008 has been a transformational year for the Company and it looks forward with confidence to further realising its potential in 2009.